Multimedia

In this Monday, Sept. 16, 2019 file photo, Rafael Mariano Grossi, who has been chosen as the new head of the International Atomic Energy Agency, IAEA, attends a news conference at the International Center in Vienna, Austria. The International Atomic Energy Agency’s board of governors selected Grossi as its new director general succeeding the late Yukiya Aman. (AP Photo/Ronald Zak)

Foto: thetimeofisrael.com

In this Monday, Sept. 16, 2019 file photo, Rafael Mariano Grossi, who has been chosen as the new head of the International Atomic Energy Agency, IAEA, attends a news conference at the International Center in Vienna, Austria. The International Atomic Energy Agency’s board of governors selected Grossi as its new director general succeeding the late Yukiya Aman. (AP Photo/Ronald Zak)

Foto: thetimeofisrael.com

In this Monday, Sept. 16, 2019 file photo, Rafael Mariano Grossi, who has been chosen as the new head of the International Atomic Energy Agency, IAEA, attends a news conference at the International Center in Vienna, Austria. The International Atomic Energy Agency’s board of governors selected Grossi as its new director general succeeding the late Yukiya Aman. (AP Photo/Ronald Zak)

Foto: thetimeofisrael.com

Ministro de Exteriores de Irán, Mohamad Javad Zarif (izda,) durante la reunión con Rafael Grossi.

Foto: Reuters

Ministro de Cultura de Cuba, Alpidio Alonso, participó en foro virtual por el Día del Instructor de Arte

Foto: Tomada de Internet

Liván Osoria milita en la Liga Francesa de Voleibol.

Foto: Tomada de Jit

Investigadores de la Universidad Atlántica de Florida en Estados Unidos identificaron el primer caso de una recién nacida a la que se le detectaron anticuerpos de coronavirus

Foto: Reuters

Novak Djokovic, ganó un nuevo título en Melbourne.

Foto: Getty Images

anticuerpo monoclonal Anti-CD6 o Itolizumab

Foto: Cortesía del CIM

El primer producto del CIM, que salió como candidato para ser utilizado por el personal de salud cubano para enfrentar la COVID-19 fue el anticuerpo monoclonal Anti-CD6 o Itolizumab que, originalmente, se ha empleado para tratar el Linfoma Cutáneo de células T y la Leucemia Linfocítica Crónica

Foto: Cortesía del CIM